Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Seeking Alpha6d
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript
Hello, and welcome to the Genmab Full Year 2024 Financial Results Conference Call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented ...
MarketWatch6d
Genmab A/S ADR
Copyright © 2025 MarketWatch, Inc. All rights reserved.
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will ...